Thiazolidinedione derivatives, useful as antidiabetic agents
申请人:Takeda Chemical Industries, Ltd.
公开号:US04687777A1
公开(公告)日:1987-08-18
Thiazolidinedione derivatives of the formula: ##STR1## and pharmacologically acceptable salts thereof are novel compounds, which exhibit in mammals blood sugar- and lipid-lowering activity, and are of value as a therapeutic agent for treatment of diabetes and hyperlipemia.
Thiazolidinedione derivatives, their production and their use
申请人:TAKEDA CHEMICAL INDUSTRIES, LTD.
公开号:EP0508740A1
公开(公告)日:1992-10-14
There is disclosed a novel thiazolidinedione derivative of the general formula (I):
wherein R1 and R2 are the same or different and are a hydrogen atom or a lower alkyl group, or a salt thereof. The thiazolidinedione derivative has hypoglycemic activity and hypolipidemic activity.
Thiazolidinedione derivatives, their production and use
申请人:Takeda Chemical Industries, Ltd.
公开号:EP0193256B1
公开(公告)日:1989-04-05
SOHDA, T.;MOMOSE, Y.;MEGURO, K.;KAWAMATSU, Y.;SUGIYAMA, Y.;IKEDA, H., ARZNEIM.-FOSRCH, 40,(1990) N, C. 37-42
作者:SOHDA, T.、MOMOSE, Y.、MEGURO, K.、KAWAMATSU, Y.、SUGIYAMA, Y.、IKEDA, H.
DOI:——
日期:——
MODULATION OF NEUROGENESIS BY PPAR AGENTS
申请人:Barlow Carrolee
公开号:US20100184806A1
公开(公告)日:2010-07-22
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more neurogenic agents, to stimulate or increase a neurogenic response and/or to treat a nervous system disease or disorder.